Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Innovation Council · Running

CAR T-REX CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment

Coordinator
Stemmatters, Biotecnologia E Mediciina Regenerativa SA, Portugal
Runs
1 April 2023 to 30 June 2027
Status
Running
EU funding
€2.7m
Total cost
€2.7m
Partners
6 organisations in 5 countries
Type
European Innovation Council
Grant agreement
101099867

What the project is doing

In the project's own words, from its summary on CORDIS.

Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gained regulatory approval, successful treatment of solid tumors using CAR T cells remains elusive. One salient problem is the limited efficacy and untimely exhaustion of CAR T cells in the tumor microenvironment (TME). Combining innovative methods of genome editing, chemistry and immunology, CAR T-REX proposes to explore a novel concept of building auto-regulated genetic circuits into CAR T cells to selectively circumvent their exhaustion upon activation in the TME.

Genetic rewiring will be achieved by precisely inserting artificial miRNAs under endogenous exhaustion-related “Driver” promoters to downregulate “Target” genes that cause exhaustion. Proprietary technology enables specific replacement of the “Driver” gene without risking off-target mutations. Further advantages of combined insertion and silencing are (i) the ability to regulate when a gene is turned on/off by biologically and clinically relevant cellular cues, and (ii) multiple gene-knockdown with a single dsDNA cleavage and RNA-silencing of both alleles.

These genetic modifications will be implemented using a novel high-performance peptide-based gene delivery platform with unlimited loading capacity, allowing combination of several types of cargo, as well as economical large scale GMP production. Rewired HER2/Neu (ErbB2) redirected CAR T cells will be tested on preclinical breast and gastric carcinomas, and variants that eliminate tumors resistant to conventional 2nd and 3rd generation peers (without adverse events) will be developed/manufactured following quality-by-design principles under GMP-like conditions, thus accelerating the pathway towards clinical translation.

These approaches will also constitute a proof-of-concept for modifying therapeutic cell products, with the potential to considerably improve their safety, specificity, efficacy, scalability and cost.

Topics

Who is involved

OrganisationCityCountryRole
Stemmatters, Biotecnologia E Mediciina Regenerativa SABarco GmrPortugalCoordinator
Stiftung Leibniz-Institut Fur ImmuntherapieRegensburgGermanyParticipant
Universidad De Santiago De CompostelaSantiago De CompostelaSpainParticipant
Debreceni EgyetemDebrecenHungaryAssociatedpartner
Debreceni EgyetemDebrecenHungaryParticipant
Targetgene Biotechnologies LtdRehovotIsraelParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI